The iShares Russell 2000 ETF has been stagnant since February 2021. Read how rising interest rates and falling 2025 earnings ...
Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback